HC Wainwright & Co. Reiterates Buy on Day One Biopharmaceutical, Maintains $50 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andres Maldonado has reiterated a 'Buy' rating on Day One Biopharmaceutical (NASDAQ:DAWN) and maintained a $50 price target.
August 08, 2023 | 10:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Day One Biopharmaceutical's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $50.
The reiteration of a 'Buy' rating and a maintained price target of $50 by HC Wainwright & Co. indicates a positive outlook for Day One Biopharmaceutical. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100